Browse News
Filter News
Found 485,638 articles
-
J&J Terminates Two Drugs From Pipeline
10/17/2017
Buried in its third-quarter financial announcement, J&J indicated it was dropping two of its pipeline drugs with little or no explanation. -
Novartis is closing its generic-drug manufacturing facility in Broomfield, Colo., which will cut 450 jobs over two years.
-
Takeda is jumping into the $40B market for NASH and other diseases of the liver with a $470M+ investment into HemoShear Therapeutics.
-
On Oct. 13, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark's Luxturna in a vote of 16 to 0.
-
Amneal and Impax are combining into a new entity that is expected to have the fifth largest generics business in the United States.
-
Backed by Atlas Venture, Lightstone Ventures and OrbiMed, Gemini has emerged with $42.5M in Series A funding and a focus on rare genetic diseases.
-
Cydan snagged $34M to fund its rare disease pipeline and also tapped two new members of its executive leadership team.
-
A San Diego bankruptcy court issued a final judgement that two former Masimo employees had misappropriated trade secrets, which they turned over to Sotera Wireless.
-
Saniona's Partner Cadent Therapeutics Receives Milestone From Novartis
10/17/2017
Cadent Therapeutics also confirmed that it expects to initiate clinical development in 2018 for the program in collaboration with Saniona.
-
ContraVir Pharmaceuticals Announces Research Collaboration Agreement with Li Ka Shing Institute of Virology
10/17/2017
The collaboration is aimed towards reaching a cure for the Hepatitis B Virus Infection.
-
The money will be to provide patient and caregiver support, funding education and investing in the community.
-
Drug R&D Boom Lead Massachusetts Biotech Jobs to Hit an All-Time High
10/17/2017
And industry trade group MassBio has the jobs numbers and pipeline data to prove it.
-
Immune Design Announces Positive FDA Feedback on Phase III Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
10/17/2017
The company plans to initiate a pivotal Phase 3 trial to support a Biologics License Application for CMB305.
-
Tonix Pharmaceuticals Reports Outcomes From U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya (Cyclobenzaprine HCI Sublingual Tablets) for PTSD
10/17/2017
Tonix is in Phase 3 development of Tonmya, an FDA-designated Breakthrough Therapy for the treatment of PTSD.
-
Diffusion Pharma Receives Final FDA Protocol Guidance for Phase III Clinical Trial with TSC in Pa...
10/17/2017
The company expects to begin trial by year-end. -
Voyager Therapeutics Announces New Data Presentations at the Congress of the European Society of ...
10/17/2017
The data includes an oral presentation related to recent results from Voyager's ongoing Phase 1b trial of VY-AADC01 in advanced Parkinson's disease. -
Eleven Biotherapeutics Appoints Richard Fitzgerald as Interim Chief Financial Officer
10/17/2017
Eleven Biotherapeutics announced the appointment of Richard F. Fitzgerald as Interim CFO, effective October 20, 2017.
-
Meet the Scientist Who's Obsessed With Discovering an Exercise Pill That Won't Give You Cancer
10/17/2017
Ronald Evans believes he’s much closer to a fat-burning, muscle-growing drug that won’t, uh, give you cancer.
-
Aduro Biotech Announces Presentation of Phase I Data for LADD-based Immunotherapy at World Confer...
10/17/2017
The Phase 1 first-in-human, open label dose-finding trial included nine patients with advanced stage relapsed or refractory non-small cell lung cancer. -
Immuron Highlights Market Opportunity Following Recent Studies on Antibiotic Correlation to C. Difficile Infections
10/17/2017
One study performed by the Minnesota Department of Health on antibiotic prescribing for dental procedures in community-associated clostridium difficile cases, which was presented at ID Week 2017.